Key result
The text describes a subscription service providing drug monographs and drug utilization evaluations, rather than reporting clinical trial results.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Content mislabeled as late-phase trial; challenges database integrity and leaves open need for verified evidence curation.
Each month, subscribers to The Formulary ® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The July 2002 Formulary monograph topics are olmesartan medoximil, fulvestrant, adalimumab, secretin, and duloxetine. The DUE is on olmesartan medoximil.
No takes yet. Share an insight, caveat, or question.
Cada et al. (2002) studied this question. The text describes a subscription service providing drug monographs and drug utilization evaluations, rather than reporting clinical trial results.
Synapse has enriched 10 related papers. Consider them for comparative context: